SOPs for BA-BE Studies V 2.0

To define the process for determining, preparing, and timing the standardized high-fat, high-calorie meals administered before drug dosing in fed state Bioavailability/Bioequivalence (BA/BE) studies, ensuring consistency across all subjects and study periods.
Click to read the full article.

To define a standardized procedure for controlling and documenting water intake before and after the administration of study drug in Bioavailability/Bioequivalence (BA/BE) studies, in alignment with regulatory requirements and clinical protocols.
Click to read the full article.

To describe the procedure for the supervision of dosing in BA/BE studies to ensure that investigational products are administered accurately and safely, in accordance with the study protocol, GCP guidelines, and regulatory requirements.
Click to read the full article.

To define a systematic approach for monitoring, identifying, recording, and managing post-dose adverse events (AEs) in subjects participating in Bioavailability/Bioequivalence (BA/BE) studies, ensuring participant safety and regulatory compliance.
Click to read the full article.

To define the standard procedure for monitoring, recording, and responding to vital sign assessments of study participants during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies, ensuring safety and compliance with protocol and regulatory guidelines.
Click to read the full article.

To establish a standard operating procedure for conducting periodic clinical safety assessments during Bioavailability/Bioequivalence (BA/BE) studies to ensure continuous monitoring of subject safety throughout the clinical trial.
Click to read the full article.

To establish a clear and systematic approach for recognizing, providing first-aid, and documenting mild adverse reactions in volunteers participating in Bioavailability/Bioequivalence (BA/BE) studies.
Click to read the full article.

To provide a clear, standardized procedure for the identification, assessment, documentation, management, and reporting of Serious Adverse Events (SAEs) in Bioavailability/Bioequivalence (BA/BE) studies.
Click to read the full article.

To define the standardized procedure for documenting all Adverse Events (AEs) occurring during the clinical phase of Bioavailability/Bioequivalence (BA/BE) studies in compliance with ICH-GCP and applicable regulatory guidelines.
Click to read the full article.

To define a clear and compliant procedure for the re-dosing of participants in cross-over Bioavailability/Bioequivalence (BA/BE) studies, ensuring protocol adherence, subject safety, and regulatory conformity.
Click to read the full article.